MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

Stock Information for MAIA Biotechnology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MAIA Biotechnology Inc.

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology Announces $736,600 Private Placement
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
MAIA Biotechnology Announces $2.25 Million Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.